Hormonal
IL-22, produced by Th22 cells, has a beneficial effect on NAFLD by alleviating steatosis and reducing transaminase levels through STAT3-mediated mechanisms, although its role in obesity pathogenesis is complex and context-dependent.
IL-22 shows promise in reducing liver fat and inflammation in NAFLD models. While not a current standalone therapy, understanding its protective role highlights the potential of targeting specific cytokine pathways for liver health. Current management focuses on weight loss and metabolic control.
In experimental settings, IL-22 seems to have a beneficial effect on multiple components of NAFLD... Recombinant IL-22 was shown to alleviate steatosis and decrease transaminase levels... IL-22 attenuates palmitate lipotoxicity
Why this rating
Strong experimental data in animal models for NAFLD benefits, but human data on obesity pathogenesis is conflicting and less definitive.
Source
The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity
Mikhaïl A. Van Herck et al. · Frontiers in Immunology · 2019
DOI 10.3389/fimmu.2019.00082
More from this paper
- Regulatory T (Treg) cells exert an attenuating effect on insulin resistance and hepatic inflammation in NAFLD and obesity, primarily through the secretion of inhibitory cytokines IL-10 and TGF-beta and PPAR-gamma-dependent functionality.Good
- Th17 cells promote liver inflammation, fibrosis, and insulin resistance in NAFLD and obesity, primarily through IL-17 secretion which stimulates pro-inflammatory cytokine release and hepatic stellate cell activation.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →